Beckman Coulter, Inc. (NYSE: BEC), a leading developer, manufacturer, and marketer of products that simplify, automate, and innovate complex biomedical testing, today announced a record contract with CML HealthCare ("CML") of Toronto, Canada. According to the company, the deal represents the largest contract of any Canadian diagnostics company for a single testing site.
Valued at an estimated $25 to $30 million over five years, Beckman Coulter will deliver nine of its flagship immunoassay (UniCel DxI 800) instruments, six chemistry (AU5421) systems and three full automation lines to CML. The new chemistry systems are upgrades to the existing Beckman Coulter systems already installed at CML.
"We are delighted to deepen our partnership with CML HealthCare, a leading provider of laboratory services in the province of Ontario, delivering the highest levels of quality healthcare," said Scott Garrett, chairman, president and CEO, Beckman Coulter. "Our instrument systems are proven to help improve diagnostic analysis and reduce the cost of care – a winning combination for CML HealthCare and every patient within its remarkable, efficient and innovative network."
CML HealthCare is a community provider of laboratory services with 121 licensed specimen collection centers and one licensed lab that process over 140,000 tests daily. The CML HealthCare network includes 110 medical imaging centers in five provinces across Canada with 79 locations in Ontario, 19 in British Columbia, nine in Alberta, two in Manitoba, and one in Quebec. CML HealthCare's business also includes 23 medical imaging centers in the U.S. Northeast with 17 centers in Maryland, five in Rhode Island and one in Delaware.
"We are driven by our commitment of providing Care, Confidence, and Comfort to our stakeholders using the highest quality diagnostic services available," said Paul Bristow, President and CEO, CML HealthCare. "Beckman Coulter's own pursuit of quality, science and innovation allows us to keep our promise to the millions of patients that we serve."